TMDX - TransMedics Group, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.70
+0.51 (+2.66%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.19
Open19.19
Bid19.80 x 1400
Ask20.50 x 1200
Day's Range19.19 - 20.30
52 Week Range15.74 - 31.54
Volume153,830
Avg. Volume195,077
Market Cap408.034M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    TransMedics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    ANDOVER, Mass., Dec. 19, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics’ Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD Donors

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the completion of the first successful adult human heart transplants from DCD (donation after circulatory death) donors in the United States at Duke University Hospital and Massachusetts General Hospital.

  • GlobeNewswire

    TransMedics Reports Third Quarter 2019 Financial Results

    ANDOVER, Mass., Nov. 06, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics Announces Change to Time of Third Quarter 2019 Earnings Conference Call on Wednesday, November 6

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will now release financial results for the third quarter of 2019 before market open on Wednesday, November 6, 2019. The corresponding conference call hosted by the TransMedics management team is now set to begin at 8:30 a.m. ET / 5:30 a.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 5969739.

  • GlobeNewswire

    TransMedics to Report Third Quarter 2019 Financial Results on November 6, 2019

    ANDOVER, Mass., Oct. 16, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

    ANDOVER, Mass., Aug. 26, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics Reports Second Quarter 2019 Financial Results

    ANDOVER, Mass., Aug. 07, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System (OCS™)

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the OCS Lung technology was used in two successful lung transplants using donor lungs from Hawaii that initially were declined for transplantation due to time and distance limitations of standard cold storage preservation. Donor lungs retrieved from Hawaii that initially were not accepted for transplantation due to limitations of cold static storage were successfully transplanted after using the OCS Lung System.  The OCS was used to reduce the ischemic injury, monitor continuously, and assess the function of the donor lungs from the time they left the donor body until they were transplanted successfully into matched recipients on the national transplant waiting list.  The first pair of lungs was transplanted in North Carolina 20+ hours after retrieval from a donor in Hawaii.  The second transplant was performed in Arizona after 9+ hours from donor to recipient.  Both transplant recipients have been discharged from the hospital.

  • GlobeNewswire

    TransMedics to Present at the 39th Annual Canaccord Genuity Global Growth Conference

    ANDOVER, Mass., July 25, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics to Report Second Quarter 2019 Financial Results on August 7, 2019

    ANDOVER, Mass., July 17, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • GlobeNewswire

    TransMedics Reports First Quarter 2019 Financial Results

    ANDOVER, Mass., June 11, 2019 -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.

  • ACCESSWIRE

    TransMedics Group, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / TransMedics Group, Inc. (NASDAQ: TMDX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on June 11, 2019 at 4:30 PM ...

  • GlobeNewswire

    TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it has received an FDA PMA approval for expanded clinical indications of the Organ Care System (OCS) Lung.  This approval will enable the OCS Lung System to be used for the preservation and ex-vivo assessment of both standard criteria donor lungs as well as the larger pool of donor lungs initially deemed unacceptable for procurement and transplantation based on limitations of cold static preservation. This approval will also enable the OCS Lung System to be used with both donors after brain death (DBD) and donors after circulatory death (DCD).  Prior to this latest FDA approval, the OCS Lung System was approved for standard criteria lungs from DBD donors only.  Based on this FDA PMA approval, TransMedics will expand its post-market Thoracic Organ Perfusion (TOP) Registry to collect long-term post-market data from recipients of all OCS Lung preserved standard criteria and initially deemed unacceptable donor lungs.

  • GlobeNewswire

    TransMedics to Report First Quarter 2019 Financial Results on June 11, 2019

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2019 after market close on Tuesday, June 11, 2019. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listening to the conference call may do so by dialing (866) 221-1172 for domestic callers or (270) 215-9603 for international callers, followed by Conference ID: 2475974.

  • GlobeNewswire

    TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    TransMedics Group, Inc. (“TransMedics”) (TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the closing of its initial public offering of 6,543,500 shares of its common stock at an initial public offering price of $16.00 per share, including 853,500 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. The shares commenced trading on The Nasdaq Global Market on May 2, 2019 under the ticker symbol “TMDX.” All of the shares were sold by TransMedics. Morgan Stanley and J.P. Morgan acted as joint lead book-running managers for the offering.